documents: FDA-2026-P-6737-0004

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2026-P-6737-0004 FDA FDA-2026-P-6737 Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling Supporting & Related Material Background Material 2026-06-15T04:00:00Z 2026 6     2026-06-15T20:27:30Z   0 0 09000064b932a274

Links from other tables